Handelsbanken Fonder AB Increases Holdings in Synopsys, Inc. $SNPS

Handelsbanken Fonder AB lifted its holdings in shares of Synopsys, Inc. (NASDAQ:SNPS) by 4.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,814 shares of the semiconductor company’s stock after purchasing an additional 2,914 shares during the period. Handelsbanken Fonder AB’s holdings in Synopsys were worth $31,142,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank bought a new stake in Synopsys in the fourth quarter worth about $730,197,000. State Street Corp grew its position in shares of Synopsys by 20.6% during the 3rd quarter. State Street Corp now owns 8,760,358 shares of the semiconductor company’s stock valued at $4,322,273,000 after acquiring an additional 1,493,912 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of Synopsys during the 4th quarter worth approximately $469,344,000. Assenagon Asset Management S.A. increased its stake in shares of Synopsys by 39.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,455,402 shares of the semiconductor company’s stock worth $1,095,281,000 after purchasing an additional 695,146 shares during the last quarter. Finally, Primecap Management Co. CA raised its holdings in shares of Synopsys by 743.6% in the 4th quarter. Primecap Management Co. CA now owns 734,800 shares of the semiconductor company’s stock worth $345,150,000 after purchasing an additional 647,700 shares during the period. 85.47% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Shelagh Glaser sold 3,394 shares of the stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $450.02, for a total value of $1,527,367.88. Following the sale, the chief financial officer directly owned 14,358 shares of the company’s stock, valued at approximately $6,461,387.16. This represents a 19.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sassine Ghazi sold 14,603 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $458.96, for a total transaction of $6,702,192.88. Following the completion of the transaction, the chief executive officer owned 75,020 shares of the company’s stock, valued at $34,431,179.20. This trade represents a 16.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.56% of the stock is owned by company insiders.

Synopsys Trading Down 0.2%

NASDAQ:SNPS opened at $410.91 on Wednesday. The company has a market cap of $78.68 billion, a P/E ratio of 95.12, a P/E/G ratio of 2.42 and a beta of 1.23. The stock’s fifty day moving average price is $429.86 and its two-hundred day moving average price is $444.81. Synopsys, Inc. has a 1 year low of $366.00 and a 1 year high of $628.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.32.

Synopsys (NASDAQ:SNPS) last posted its quarterly earnings results on Wednesday, May 27th. The semiconductor company reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.15 by $0.20. Synopsys had a return on equity of 5.83% and a net margin of 8.91%.The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.25 billion. During the same period last year, the company earned $3.67 earnings per share. The business’s revenue for the quarter was up 41.9% on a year-over-year basis. Synopsys has set its FY 2026 guidance at 14.720-14.800 EPS and its Q3 2026 guidance at 3.630-3.690 EPS. As a group, analysts expect that Synopsys, Inc. will post 10.65 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Robert W. Baird set a $558.00 price objective on Synopsys in a research note on Thursday, May 28th. BNP Paribas Exane boosted their target price on Synopsys from $425.00 to $450.00 and gave the company an “underperform” rating in a research note on Thursday, May 28th. Piper Sandler upgraded Synopsys from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $450.00 to $550.00 in a research note on Tuesday, June 23rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Synopsys in a report on Monday, June 8th. Finally, Benchmark began coverage on Synopsys in a research note on Wednesday, July 15th. They issued a “buy” rating and a $570.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $565.06.

About Synopsys

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.